Crinetics Pharmaceuticals, Inc.
CRNXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Crinetics Pharmaceuticals, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 9 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 22, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| SIMPLEX TRADING, LLC | 2026-03-31 | 108 | $3.92K | SEC filing |
| Hood River Capital Management LLC | 2026-03-31 | 907,412 | $33M | SEC filing |
| Virtus Investment Advisers, LLC | 2026-03-31 | 16,721 | $607K | SEC filing |
| Larson Financial Group LLC | 2026-03-31 | 64 | $2.32K | SEC filing |
| Corient Private Wealth LLC | 2026-03-31 | 18,564 | $672K | SEC filing |
| China Universal Asset Management Co., Ltd. | 2026-03-31 | 18,581 | $675K | SEC filing |
| Keating Financial Advisory Services, Inc. | 2026-03-31 | 5 | $182 | SEC filing |
| Private Wealth Management Group, LLC | 2026-03-31 | 134 | $4.87K | SEC filing |
| STATE STREET CORP | 2026-03-31 | 2,403,046 | $87.3M | SEC filing |
| ADAR1 Capital Management, LLC | 2026-03-31 | 1,139,331 | $41.4M | SEC filing |
| NEW YORK STATE COMMON RETIREMENT FUND | 2026-03-31 | 141,618 | $5.14M | SEC filing |
| Fiera Capital Corp | 2026-03-31 | 589,654 | $21.4M | SEC filing |
| CoreCap Advisors, LLC | 2026-03-31 | 14 | $508 | SEC filing |
| Root Financial Partners, LLC | 2026-03-31 | 14 | $508 | SEC filing |
| WELLS FARGO & COMPANY/MN | 2026-03-31 | 73,652 | $2.68M | SEC filing |
| Candriam S.C.A. | 2026-03-31 | 830,961 | $30.2M | SEC filing |
| SANDERS MORRIS HARRIS LLC | 2026-03-31 | 21,100 | $766K | SEC filing |
| CANADA LIFE ASSURANCE Co | 2026-03-31 | 10,596 | Not shown | SEC filing |
| Siren, L.L.C. | 2026-03-31 | 1,903,636 | $69.1M | SEC filing |
- Each value is checked against Crinetics Pharmaceuticals, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Crinetics Pharmaceuticals, Inc.'s share price.
- 1 row left out: the value per share it reports is far from Crinetics Pharmaceuticals, Inc.'s share prices on file from around the report date, far from the value most filers reported for that date, or the value of a security already left out, so it may describe another security or share class.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Crinetics Pharmaceuticals, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-04-08 · Knight Jeff E.: Larger than 66 of the 68 other insider sales of Common Stock on file. SEC filing
- 2025-08-22 · Pizzuti Dana: Larger than 62 of the 68 other insider sales of Common Stock on file. SEC filing
- 2025-06-12 · Betz Stephen F.: Larger than 67 of the 68 other insider sales of Common Stock on file. SEC filing
- 2024-06-28 · Wilson Marc: Larger than 64 of the 68 other insider sales of Common Stock on file. SEC filing
- 2024-05-08 · Struthers Richard Scott: Larger than all 68 other insider sales of Common Stock on file. SEC filing
- 2024-04-04 · Struthers Richard Scott: Larger than 65 of the 68 other insider sales of Common Stock on file. SEC filing
- 2024-03-22 · Knight Jeff E.: Larger than 62 of the 68 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-17 | Okey Stephanie · Director | Common Stock | S — Open market or private sale | −608 | 36.22 | SEC filing |
| 2026-06-17 | Okey Stephanie · Director | Common Stock | S — Open market or private sale | −6,292 | 35.62 | SEC filing |
| 2026-04-08 | Knight Jeff E. · Chief Dev. & Operating Officer | Common Stock | S — Open market or private sale | −85,163 | 40.10 | SEC filing |
| 2026-03-16 | Betz Stephen F. · Chief Scientific Officer | Common Stock | S — Open market or private sale | −6,371 | 37.11 | SEC filing |
| 2026-03-16 | Struthers Richard Scott · President & CEO | Common Stock | S — Open market or private sale | −13,196 | 37.11 | SEC filing |
| 2026-03-16 | Knight Jeff E. · Chief Operating Officer | Common Stock | S — Open market or private sale | −5,950 | 37.11 | SEC filing |
| 2026-03-16 | Knight Jeff E. · Chief Operating Officer | Common Stock | S — Open market or private sale | −3,961 | 37.77 | SEC filing |
| 2026-03-16 | Betz Stephen F. · Chief Scientific Officer | Common Stock | S — Open market or private sale | −4,241 | 37.77 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-18 | Fust Matthew K · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,730 | SEC filing |
| 2026-06-18 | Nichols Weston · Director | Common Stock | A — Grant, award, or other acquisition | +5,925 | SEC filing |
| 2026-06-18 | Fust Matthew K · Director | Common Stock | A — Grant, award, or other acquisition | +5,925 | SEC filing |
| 2026-06-18 | Okey Stephanie · Director | Common Stock | A — Grant, award, or other acquisition | +5,925 | SEC filing |
| 2026-06-18 | Deardorf Caren · Director | Common Stock | A — Grant, award, or other acquisition | +5,925 | SEC filing |
| 2026-06-18 | Bedrosian Camille L · Director | Common Stock | A — Grant, award, or other acquisition | +5,925 | SEC filing |
| 2026-06-18 | Bedrosian Camille L · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,730 | SEC filing |
| 2026-06-18 | Vivaldi Coelho Rogerio · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +9,730 | SEC filing |
Showing 8 of 36 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2024-11-20 | Wilson Marc · CFO | Common Stock | J — Other acquisition or disposition | +473 | SEC filing |
| 2024-11-20 | Betz Stephen F. · Chief Scientific Officer | Common Stock | J — Other acquisition or disposition | +451 | SEC filing |
Showing 2 of 2 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.